April 1, 2001Annals of Pharmacotherapy
Argatroban for Prevention and Treatment of Thromboembolism in Heparin-Induced Thrombocytopenia
Why the study?
Does argatroban reduce the composite end point of death, amputation, and new thrombosis compared to historical controls in patients with heparin-induced thrombocytopenia?
Population
Patients with heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITTS)
Comparison
Argatroban vs Historical controls
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support argatroban consideration in HIT; leaves open randomized confirmation versus contemporary controls.
Structured PICO
Does argatroban reduce the composite end point of death, amputation, and new thrombosis compared to historical controls in patients with heparin-induced thrombocytopenia?
P
Population
Patients with heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITTS)
I
Intervention
Argatroban (initiated at 2 microg/kg/min and adjusted to maintain activated partial thromboplastin time at 1.5-3 times baseline)
C
Comparator
Historical controls
O
Outcome
Composite end point of death, amputation, and new thrombosiscomposite
Argatroban improves clinical outcomes in patients with HIT and HITTS compared with historical controls and offers practical advantages in dosing, monitoring, and reversibility.
Cite This Study
Kondo et al. (2001) studied this question.